Literature DB >> 1797890

Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure.

P Toft1, L Heslet, M Hansen, N A Klitgaard.   

Abstract

The pharmacokinetics of theophylline and ethylenediamine were examined in 6 patients with septicaemia and multiorgan failure (MOF). The patients received a bolus injection of 4 mg/kg aminophylline. Aminophylline is the ethylenediamine salt of theophylline. The clearance of theophylline was reduced in all our patients ranging from 10-66% of the value obtained in healthy volunteers. The median t 1/2 beta was 18.8 h (range 5.8-25.5) compared to a normal value of 6 h. The median clearance of ethylenediamine was 54% of the normal value, while the peripheral volume of distribution was increased to 650%. Due to this t 1/2 beta was 2.3 (2.0-2.7) h, which is 5 times the normal value of 0.55 h. There was no correlation between clearance of theophylline and ethylenediamine. As theophylline has a narrow therapeutic range, routine monitoring with measurements of serum theophylline is mandatory in patients with MOF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797890     DOI: 10.1007/BF01690768

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  15 in total

1.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

2.  Theophylline pharmacokinetics after intravenous infusion with ethylenediamine or sodium glycinate.

Authors:  J Caldwell; A H Staib; I A Cotgreave; M Siebert-Weigel
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

3.  Inhibition of antipyrine metabolism by interferon.

Authors:  S J Williams; G C Farrell
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline.

Authors:  S Vozeh; G Kewitz; A Perruchoud; M Tschan; C Kopp; M Heitz; F Follath
Journal:  Am Rev Respir Dis       Date:  1982-02

5.  The effect of acute and chronic renal failure on theophylline clearance.

Authors:  L A Bauer; S P Bauer; R A Blouin
Journal:  J Clin Pharmacol       Date:  1982-01       Impact factor: 3.126

6.  Pharmacokinetics of theophylline in hepatic disease.

Authors:  A Mangione; T E Imhoff; R V Lee; L Y Shum; W J Jusko
Journal:  Chest       Date:  1978-05       Impact factor: 9.410

7.  Ethylenediamine-induced asthma.

Authors:  S Lam; M Chan-Yeung
Journal:  Am Rev Respir Dis       Date:  1980-01

8.  Reduced drug elimination in congestive heart failure. Studies using aminopyrine as a model drug.

Authors:  G W Hepner; E S Vesell; K R Tantum
Journal:  Am J Med       Date:  1978-08       Impact factor: 4.965

9.  Pharmacokinetics and metabolism of theophylline in patients with liver diseases.

Authors:  A H Staib; D Schuppan; R Lissner; W Zilly; G von Bomhard; E Richter
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-11

10.  Hypersensitivity reactions to ethylenediamine in aminophylline.

Authors:  J A Elias; A I Levinson
Journal:  Am Rev Respir Dis       Date:  1981-05
View more
  2 in total

Review 1.  Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

Authors:  Peter De Paepe; Frans M Belpaire; Walter A Buylaert
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Impact of Inflammation on Cytochromes P450 Activity in Pediatrics: A Systematic Review.

Authors:  Camille Lenoir; Frédérique Rodieux; Jules A Desmeules; Victoria Rollason; Caroline F Samer
Journal:  Clin Pharmacokinet       Date:  2021-08-31       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.